Viking Therapeutics, Inc. (VKTX) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 28 days, typically, give or take 7 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Oct 28, 2026after close 28 8-K
Q2 FY2026Wed, Jul 29, 2026after close 29 8-K
Q1 FY2026Wed, Apr 29, 2026after close 29 8-K
Q4 FY2025Wed, Feb 11, 2026after close 42 8-K
Q3 FY2025Wed, Oct 22, 2025after close 22 8-K
Q2 FY2025Wed, Jul 23, 2025after close 23 8-K
Q1 FY2025Wed, Apr 23, 2025after close 23 8-K
Q4 FY2024Wed, Feb 5, 2025after close 36 8-K

What they guided beta

Q3 FY2026 "Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027." exhibit
Q3 FY2026 "The company expects these studies to be completed in 2027." exhibit
Q3 FY2026 "The company anticipates the results of the extension studies to be available in 2028." exhibit
Q3 FY2026 "Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027." exhibit
Q3 FY2026 "The company expects the results from Part 2 of this study to be available in 2027." exhibit
Q2 FY2026 "Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash Position of $502 Million --" exhibit
Q2 FY2026 "During the period, the company continued to prepare for initiation of Phase 3 trials with the oral formulation of VK2735, expected to begin in the fourth quarter of this year." exhibit
Q2 FY2026 "To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 5, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 7609005 ." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VKTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VKTX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

VKTX earnings date badge

HTML

<a href="https://veritasdata.dev/company/VKTX/"><img src="https://veritasdata.dev/embed/VKTX.svg" alt="VKTX earnings date" width="240" height="56"></a>

Markdown

[![VKTX earnings date](https://veritasdata.dev/embed/VKTX.svg)](https://veritasdata.dev/company/VKTX/)

Script

<script async src="https://veritasdata.dev/embed/VKTX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VKTX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.